GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » BioLife Solutions Inc (NAS:BLFS) » Definitions » EV-to-EBIT

BioLife Solutions (BioLife Solutions) EV-to-EBIT

: -11.73 (As of Today)
View and export this data going back to 1992. Start your Free Trial

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, BioLife Solutions's Enterprise Value is $675.0 Mil. BioLife Solutions's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-57.5 Mil. Therefore, BioLife Solutions's EV-to-EBIT for today is -11.73.

The historical rank and industry rank for BioLife Solutions's EV-to-EBIT or its related term are showing as below:

BLFS' s EV-to-EBIT Range Over the Past 10 Years
Min: -340.88   Med: -7.37   Max: 1877.18
Current: -11.73

During the past 13 years, the highest EV-to-EBIT of BioLife Solutions was 1877.18. The lowest was -340.88. And the median was -7.37.

BLFS's EV-to-EBIT is ranked worse than
100% of 465 companies
in the Medical Devices & Instruments industry
Industry Median: 19.21 vs BLFS: -11.73

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. BioLife Solutions's Enterprise Value for the quarter that ended in Dec. 2023 was $725.0 Mil. BioLife Solutions's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-57.5 Mil. BioLife Solutions's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -7.94%.


BioLife Solutions EV-to-EBIT Historical Data

The historical data trend for BioLife Solutions's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioLife Solutions Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 431.01 -309.83 -49.45 -19.06 -12.60

BioLife Solutions Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBIT Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -19.06 -20.52 44.57 157.52 -12.60

Competitive Comparison

For the Medical Instruments & Supplies subindustry, BioLife Solutions's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioLife Solutions EV-to-EBIT Distribution

For the Medical Devices & Instruments industry and Healthcare sector, BioLife Solutions's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where BioLife Solutions's EV-to-EBIT falls into.



BioLife Solutions EV-to-EBIT Calculation

BioLife Solutions's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=675.026/-57.532
=-11.73

BioLife Solutions's current Enterprise Value is $675.0 Mil.
BioLife Solutions's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-57.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioLife Solutions  (NAS:BLFS) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

BioLife Solutions's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=-57.532/724.963
=-7.94 %

BioLife Solutions's Enterprise Value for the quarter that ended in Dec. 2023 was $725.0 Mil.
BioLife Solutions's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-57.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioLife Solutions EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of BioLife Solutions's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


BioLife Solutions (BioLife Solutions) Business Description

Traded in Other Exchanges
Address
3303 Monte Villa Parkway, Suite 310, Bothell, WA, USA, 98021
BioLife Solutions Inc is active in the healthcare segment. The company is engaged in developing, manufacturing and marketing a portfolio of biopreservation tools and services for cells, tissues and organs, including clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud, hosted biologistics cold chain management application for shippers. The company's product offerings include hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs.
Executives
Geraint Phillips officer: SVP, Global Operations 3303 MONTE VILLA, #310, BOTHELL WA 98021
Sarah Aebersold officer: VP, Global Human Resources BIOLIFE SOLUTIONS, INC., 3303 MONTE VILLA PARKWAY, BOTHELL WA 98021
Troy Wichterman officer: Chief Financial Officer 3303 MONTE VILLA PARKWAY, BOTHELL WA 98021
Greef Roderick De director
Aby J. Mathew officer: Chief Tech. Officer & Sr. VP 3303 MONTE VILLA PARKWAY, #310, BOTHELL WA 98021
Todd Berard officer: Vice President, Marketing 3303 MONTE VILLA PARKWAY, SUITE 310, BOTHELL WA 98021
Karen A. Foster officer: Vice President of Operations C/O BIOLIFE SOLUTIONS, INC., 3303 MONTE VILLA PARKWAY, SUITE 310, BOTHELL WA 98021
Michael Rice director, officer: President & CEO C/O BIOLIFE SOLUTIONS, INC., 171 FRONT STREET, OWEGO NY 13827
Casdin Partners Master Fund, L.p. 10 percent owner WALKER HOUSE, 87 MARY STREET, GEORGE TOWN E9 KY1-9001
Garrie Richardson officer: Chief Revenue Officer 3303 MONTE VILA PARKWAY, BOTHELL WA 98021
Marcus Schulz officer: Vice President, Global Sales 3303 MONTE VILLA PARKWAY, SUITE 310, BOTHELL WA 98021
Joseph C Schick director 16719 NE 139TH PLACE, WOODINVILLE WA 98072
Amy Duross director 8410 GOLDEN BEAR PLACE, WHISTLER A1 V8E 1J7
Timothy L. Moore director C/O KITE PHARMA, INC., 2225 COLORADO AVE., SANTA MONICA CA 90404
Joydeep Goswami director SUMITOMO FUDOSAN MITA TWIN BLDG, EAST WING 4-2-8 SHIBAURA MINATO-KU, TOKYO M0 1080023